1 Title: Dopamine modulates the neural representation of subjective value of food in 2 hungry subjects 3 4 **Abbreviated title:** Dopamine modulates the neural representation of value 5 6 **Authors:** Medic, Nenad 7 8 ¹ Dept. of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK 9 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 10 CB2 0QQ, UK 11 nm483@cam.ac.uk 12 Ziauddeen, Hisham 13 14 ¹ Dept. of Psychiatry, University of Cambridge, Cambridge, CB2 0SZ, UK ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 15 16 CB2 0QQ, UK 17 ³ Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge CB21 5EF, UK 18 hz238@cam.ac.uk 19 20 Vestergaard, Martin D ⁴ Dept. of Physiology, Development and Neuroscience, University of Cambridge, Cambridge 21 CB2 3DY, UK 22 23 mdv23@cam.ac.uk 24 25 Henning, Elana 26 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK 27

28 eh330@medschl.cam.ac.uk 29 Schultz, Wolfram 30 31 ⁴ Dept. of Physiology, Development and Neuroscience, University of Cambridge, Cambridge 32 CB2 3DY, UK 33 ws234@cam.ac.uk 34 35 Farooqi, I Sadaf ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 36 37 CB2 0QQ, UK 38 isf20@cam.ac.uk 39 40 Fletcher, Paul C ¹ Dept. of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK 41 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 42 43 CB2 0QQ, UK 44 ³ Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge CB21 5EF, UK 45 pcf22@cam.ac.uk 46 **Corresponding author:** 47 Medic, Nenad 48 Wellcome Trust-MRC Institute of Metabolic Science 49 50 Level 4, Addenbrooke's Hospital, University of Cambridge 51 Box 289, CB2 0QQ, Cambridge, UK 52 +44-1223-761219 nm483@cam.ac.uk 53 54

Number of pages: 40 **Number of figures:** 5 Number of tables: 4 Number of words: a) Abstract: 141 words **b) Introduction:** 475 words **c) Discussion:** 1479 words d) Total: 8007 words **Conflict of interest:** The authors declare no conflict of interest. **Acknowledgements:** We thank all the participants and the staff of the Wolfson Brain Imaging Centre. This study was supported by the NIHR/Wellcome Trust Clinical Research Facility, Bernard Wolfe Health Neuroscience Fund (HZ, EH, ISF, PCF), the Wellcome Trust (NM, HZ, MDV, EH, WS, ISF, PCF), the NIHR Cambridge Biomedical Research Centre (EH, ISF), the European Research Council (MDV, WS) and the National Institutes of Health Caltech Conte Center (MDV, WS).

Dopamine modulates the neural representation of subjective value of food in hungry

subjects

Abstract

While there is a rich literature on the role of dopamine in value learning, much less is known about its role in using established value estimations to shape decision-making. Here we investigated the effect of dopaminergic modulation on value-based decision-making for food items in fasted healthy human participants. The Becker-deGroot-Marschak auction, which assesses subjective value, was examined in conjunction with pharmacological functional magnetic resonance imaging (fMRI) using a dopaminergic agonist and an antagonist. We found that dopamine enhanced the neural response to value in the inferior parietal gyrus/intraparietal sulcus, and that this effect predominated towards the end of the valuation process when an action was needed to record the value. Our results suggest that dopamine is involved in acting upon the decision, providing additional insight to the mechanisms underlying impaired decision-making in healthy individuals and clinical populations with reduced dopamine levels.

Introduction

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

Successful interactions with the environment - those that maximise reward and minimise punishment – entail using previous experience to predict the likely value of outcomes and the actions that obtain them. Animal and human studies have strongly implicated the neurotransmitter dopamine in this value learning process (Bayer and Glimcher, 2005; Schultz, 1998; Schultz et al., 1997; Steinberg et al., 2013; Wise, 2004; Frank and O'Reilly, 2006; Frank et al., 2004; Pessiglione et al., 2006), in addition to its other overlapping roles in shaping behaviour, including motivation (Berridge and Robinson, 1998), vigour (Niv et al., 2007) and behavioural activation (Robbins and Everitt, 2007). But choice requires not merely an ability to predict the consequences of one's actions. One must be able to weigh up the likely values of competing possibilities. Thus, it is critical to retrieve and represent the subjective values of the options on offer in order to select the most valuable one. This value computation – an intrinsic part of decision-making - has been linked to the function of certain key brain regions in humans and non-human primates, including the ventromedial prefrontal cortex (vmPFC), ventral striatum, posterior parietal and supplementary motor cortex (Bartra et al., 2013; Clithero and Rangel, 2013; Hunt et al., 2012; O'Doherty, 2011; Platt and Glimcher, 1999; Wunderlich et al., 2009). The key question posed in the current study is whether value-related processes in these regions may be modulated by dopamine. Single cell recordings from dopamine neurons responding to reward-predicting stimuli have implicated dopamine in the neural coding of the subjective value of stimuli (Fiorillo et al., 2003; Roesch et al., 2007; Tobler et al., 2005). Furthermore, recent pharmacological studies suggested a role of dopamine in the optimal selection of most valuable stimuli within probabilistic learning tasks (Jocham et al., 2011; Shiner et al., 2012; Smittenaar et al., 2012). However, there is a critical distinction between value updating (learning) and value-based decision-making, and these cannot be fully dissociated within probabilistic learning tasks. Whereas both processes are hypothesised to be modulated by dopamine (McClure et al., 2003), the distinct role of

decision-making.

dopamine in decision-making, dissociated from learning, has not been experimentally investigated. To address this, we conducted a between-subject, placebo-controlled pharmacological fMRI study in healthy volunteers.

We explored the effects of both a dopamine agonist and an antagonist on the subjective valuation of food items in a Becker-deGroot-Marschak (BDM) mechanism (Becker et al., 1964). The BDM replicates many aspects of second-price auctions and provides a robust means of obtaining subjective values and involves no learning component. It has been used in human neuroscience before (Grether et al., 2007; Plassmann et al., 2007). All items in the auction were well-known everyday foods whose value subjects would have acquired through life experience,

independent of our experimental manipulation. This enabled us to characterise the impact of

dopaminergic modulation on the behavioural and brain processes associated primarily with

Materials and methods

Subjects

Forty-seven healthy, right-handed people (23 males, aged 23.8 ± 3.2 , body mass index 21.7 ± 1.6 kg/m² (mean \pm SD)) participated in the study. All subjects had normal or corrected to normal vision, had no history of psychiatric or other significant medical history, and reported no contraindications to the pharmacological agents or MRI scanning.

The study was approved by the Cambridge East Local Research Ethics Committee (REC 11/EE/0480) and was conducted at the Wellcome Trust Clinical Research Facility and the Wolfson Brain Imaging Centre in Addenbrooke's Hospital, Cambridge, UK. The study was carried out in accordance with the principles of the Declaration of Helsinki. All participants provided written, informed consent.

Study design

In a double-blind, between-subject study, subjects received a single oral dose of either bromocriptine 1.25 mg (dopamine D2 agonist, n=15), sulpiride 400 mg (D2 antagonist, n=16) or placebo (n=16). One subject (from the sulpiride group) did not pay attention to the task and was excluded from the analysis (on over 50% of the free trials, the subject placed a bid of £0; when debriefed, she did not express any dislike of the food items on offer or a desire to keep her budget, thus calling into question her understanding of the task). Three additional subjects (one from each group) were excluded from the fMRI analysis because of severe signal dropout in the frontal lobe, as agreed on visual inspection by the study analysis team. This left 46 datasets (23 males, aged 23.8 \pm 3.2, body mass index 21.7 \pm 1.6 kg/m² (mean \pm SD)) for the behavioural analysis and 43 datasets (21 males, aged 23.6 \pm 2.9, body mass index 21.5 \pm 1.5 kg/m² (mean \pm SD)) for the fMRI analysis. Subjects' age (F = 0.45, p = 0.64), BMI (F = 1.02, p = 0.37) or gender (χ^2 = 0.04, p = 0.98) did not differ between the treatment groups. In addition to the task described below, participants underwent a number of other cognitive measures, which are not presented here.

Subjects attended the study session in the morning following an overnight fast. They received a standardised breakfast (based on body weight, age and gender) on the clinical research facility at 8am. This was to ensure similar baseline metabolic states across subjects and to minimise pharmacokinetic perturbations related to food and drink.

Bromocriptine and sulpiride have been used in previous studies (Cools et al., 2009; Dodds et al., 2009; Morcom et al., 2010), and are well tolerated at these doses. As bromocriptine can cause nausea (Bromocriptine SPC, 2012), to maintain the double-blinding and prevent any effects of nausea on performance on a food-related task, all subjects were prophylactically given 10 mg of the anti-emetic domperidone, which does not cross the blood-brain barrier (Domperidone SPC, 2012). Bromocriptine reaches peak plasma levels 1-3 hours post dose, with a half-life of about 15 hours (Kvernmo et al., 2006). Sulpiride reaches its maximal plasma concentration about 3 hours post dose, and has a plasma half-life of about 12 hours (Caley and Weber, 1995; Wiesel et al., 1980). The study drug and domperidone were given to all participants at 11am. The fMRI acquisition started approximately 2.5 hours after receiving the drugs (at ~1:30 pm) to capture the window of maximal drug effect.

fMRI task

A computerised version of the BDM auction was developed, in which participants could bid for 50 different foods, represented by photographs (see Figure 1A). Participants were given a fixed budget, and the auction procedure incentives participants to place bids as close as possible to their real subjective value.

In addition to their study participation fee, before entering the scanner, participants were handed a budget of £3 for bidding. This was physically given to them to ensure they regarded the budget as their own money. They were instructed that on each trial they could place a bid between £0 and £3 for the presented item. Responses were made on a sliding scale that went from £0 to £3 in increments of 20 pence. Participants were told that the computer would bid against them on each trial but the bid would not be disclosed to them. As per the rules of the

auction, one trial would be randomly selected at the end of the auction (subjects therefore did not have to spread their £3 budget across different trials, and were instructed to treat every trial as if it were the only one). If their bid for the food item on the selected trial was larger than the computer's, they would win that food item, get a chance to eat it after the scanning session and only have to pay the amount the computer bid (which would be less than their bid) and keep any remaining change. If, however, the computer outbid them or matched their bid, they would not win the food item but would get to keep their £3 budget. Given this set-up, the auction is incentive-compatible, i.e. the best strategy is to place a bid close to what one is actually willing to pay. As the actual amount paid is determined by the computer's bid on the selected trial, bidding higher amounts risks having to pay more than one's subjective value. Bidding lower amounts runs the risk of losing the opportunity to win the item (more cheaply than one was prepared to pay for it). These rules were all explicitly stated and emphasised to the subjects as part of the task instructions. Critically, participants were in a hungry state and were told that they could eat any food they won after the scanning session.

Since each trial entails a number of perceptuomotor components, we used an approach taken by Plassmann et al., (2007), by including a control task in which the same 50 foods were presented in "forced" trials (as opposed to the above "free" trials) where subjects were instructed to bid an amount taken from a random distribution of possible bids from £0 to £3 pounds, again in 20 pence increments. These trials required participants to engage in all the processes involved in the free trials with the critical difference of requiring no subjective valuation. Moreover, participants were aware that they would not lose money on such trials.

Fifty trials of each trial type (free and forced), of duration 8 seconds, were presented in a randomised order. The picture of the food was presented throughout the entire 8-second duration of a trial. The initial position of the cursor on the sliding scale varied randomly. Participants placed bids using a standard button box with the first and second buttons serving to move the cursor down or up the sliding value scale in steps of 20 pence, and the third button

serving to confirm the final bid and mark the end of the bidding. From this point until the end of the 8-second bidding trial, the cursor could not be moved further. When the 8-second bidding trial was over, a feedback screen showing the final bid was presented (Figure 1A). If the bid was not confirmed within 8 seconds, the feedback screen stated "Not quick enough". In the analysis, these trials were considered missed trials.

In fact, for practical reasons, the task was set up to ensure that subjects did not win a food item, but instead ended up keeping their £3 budget.

Behavioural analysis

Behavioural data were analysed using mixed-effects models (nlme package in R (Pinheiro et al., 2013)), with subjects as a random effect. Post-hoc comparisons, where needed, were done using the multcomp package (Hothorn et al., 2008).

fMRI data acquisition and analysis

All data were acquired on a Siemens Verio scanner operating at 3 Tesla with a 192mm field of view at the Wolfson Brain Imaging Centre, Cambridge, UK. A total of 570 gradient echo T2*-weighted echo planar images (EPI) depicting blood oxygenation level dependent (BOLD) contrast were acquired for each participant. The first six images were discarded to avoid T1 equilibration effects. Images comprised 31 slices, each 3mm thick with a 0.8mm inter-slice gap and a 64×64 data matrix. Slices were acquired in an ascending interleaved fashion, repetition time = 2000ms, echo time = 30ms, flip angle = 78° , axial orientation = oblique. Data were analysed using statistical parametric mapping in the SPM8 program (www.fil.ion.ucl.ac.uk). Images were realigned then spatially normalised to a standard template and spatially smoothed with an isotropic 3 dimensional Gaussian filter (8 mm full width at half maximum). The time series in each session were high-pass filtered (with cut-off frequency 1/120 Hz) and serial autocorrelations were estimated using an AR(1) model.

Model 1: Brain responses to value across the entire bidding period and its modulation by

dopamine

Each bidding trial was modelled as a boxcar function, from the onset of the food stimulus until the bid was confirmed (duration equal to RT, Figure 1B). Separate regressors were created for free and forced trials. Free and forced bids were used as parametric modulators of these regressors. Missed trials (in which no bids were selected within 8 seconds) were modelled as a separate regressor. All regressors were convolved with a canonical haemodynamic response function with a temporal derivative. Six motion realignment parameters were included as regressors of no interest.

To examine processes specifically associated with valuation, we calculated the first-level contrasts as the difference between the parametric modulator of free bid in free trials and forced bid in forced trials. Given that in forced trials subjects implemented instructed bids, these trials should not engage the circuitry of interest to us but they should engage all other non-specific processes related to valuation. The applied contrast thus corrects for non-specific effects and enables identification of regions specifically involved in the valuation-based decision process. Single-subject contrast images were then entered into a second-level group analysis, with subjects as a random effect.

At the second level, two analyses were performed:

1. To explore which brain regions are involved in valuation across all subjects, independent of pharmacological treatment, we computed a one-sample t-test on the single-subject contrast coefficients from all 43 participants. The analysis was conducted within a pre-defined 10mm radius sphere in the vmPFC (from the work of Chib et al. (2009)), with a family-wise error (FWE) small-volume corrected threshold of p<0.05. This was based on our a priori hypothesis given the strong evidence implicating this region in value computation. In addition, we explored the existence of value related signals across the whole brain, adopting a threshold of p<0.05,

FWE corrected at the cluster-level. Additionally, for completeness, we explored the existence of brain regions whose neural activity separately correlated with free bids in free trials and forced bids in forced trials. We also explored whether there was a region whose activity tracked the mismatch between free bid and the randomly ascribed forced bid for the same food item during forced trials; this entailed examining the existence of correlation between neural activity during forced trials and a parametric modulator of the difference between the free bid and the randomly ascribed forced bid for same food item. These additional analyses were conducted at the whole-brain level, using a more liberal threshold of p<0.001, uncorrected.

2. To explore the effect of the dopaminergic modulation on the neural representation of value, we performed a non-directional F-test (ANOVA). This was again conducted within the vmPFC ROI, applying a small-volume corrected threshold of p<0.05, and at the whole-brain level, at a more liberal threshold of p<0.001 uncorrected, k>20 voxels. This threshold at the whole-brain level was adopted because it is not possible to apply a cluster-level correction for F-tests in SPM8 and a voxel-level correction would be too stringent. In case of significant effects, they were further delineated using two-sample t-tests at the whole-brain cluster-level and within the vmPFC sphere, at a FWE corrected threshold of p<0.05.

Model 2: Does dopamine have different contributions to different phases of the bidding/valuation process?

This post-hoc analysis aimed to establish the temporal specificity of the dopaminergic effects and, in so doing, to relate them to the early (initial valuation) and late (value-dependent action) stages of the bidding process. A modified first-level model was estimated that looked for changes in the correlation of BOLD activity with the bid separately for early and late phases of each trial.

To model the early and late stages of the bidding process, two regressors were created for each

subject. These two regressors were modelled as 0s stick functions: an early period regressor was set at the time of food photo (and trial) onset, and a late period regressor was set at a time half-way from the food photo onset to the bid confirmation (RT/2). This was done separately for each trial (Figure 1C). Whereas at the first time point no responding took place, at the second time point, participants were responding to select the bid. Missed early and late regressors were modelled as separate 0s stick functions, with the late time point regressor modelled at 4s (halfway through the trial). The parametric modulators of bids for early and late time points were the same for a given trial. To identify neural representations of value at each time point, two separate single-subject contrasts were computed: the early neural representation of value as the difference between the parametric modulator of free bid and forced bid at the early time point; and the late neural representation as the difference between the parametric modulator of free bid and forced bid at the late time point.

The two contrast images per each individual were put forward to the second-level group analysis, with subjects as a random effect. At the group level we used a 2x3 factorial ANOVA to explore the interaction between time and drug on the neural representation of value. This analysis was confined to a 10mm-radius sphere around the peak voxel exhibiting the strongest dopaminergic modulation of neural representation of value, established in the previous analysis. The analysis was conducted at a FWE small-volume corrected threshold of p<0.05.

Results

Behavioural results

Missed trials

- Predictably, there were significantly fewer missed trials within the free than in the forced trials
- 312 (free (mean±SEM): 0.48± 0.12, forced (mean±SEM): 1.52± 0.27, F=17.49, p=0.0001), however
- 313 this did not differ across groups (trial type-by-group interaction F=0.14, p=0.87).

Bid

Despite a clear trend for higher free bids in the sulpiride group (Figure 2A), the effect of treatment did not reach significance (F=2.83, p=0.07). Pairwise comparisons revealed a strongest difference between sulpiride and bromocriptine, however this did not reach significance (sulpiride versus bromocriptine, z=2.16; p=0.08, placebo versus bromocriptine z=0.23, p=0.97; sulpiride versus placebo z=1.96, p=0.12, Tukey-corrected for multiple

320 comparisons).

Free bids were found to be positively correlated with the initial random position of cursor on the bidding scale (t=6.09, p<0.0001), however, this did not differ between different treatment groups (initial cursor position-by-treatment group interaction F=1.76, p=0.17). Adding the initial cursor position as the covariate into the model exploring the effect of treatment group on

the bid did not change the reported results.

Reaction time

Individual reaction times (RTs) were, of course, dependent on the initial position of the cursor since this would determine how far they were required to move in order to finalise the selection. There was thus a correlation between starting point and RT (t=10.15, p<0.0001). To account for this, the number of button presses made to select the bid was entered as a covariate into the model exploring the effect of trial type and drug treatment on RT. The analysis revealed

a significant effect of trial type (F=398.39, p<0.0001), with subjects, as expected, being quicker on forced compared to free trials (Figure 2B). There was no main effect of treatment (F=1.01, p=0.37), however there was a significant treatment-by-trial type interaction (F=3.7, p=0.025). None of the pairwise comparisons between drug treatments in the free condition reached significance, however, as evident from the plot, there was a trend of shorter RTs under sulpiride in comparison to placebo and bromocriptine (placebo versus bromocriptine z=0.47, p=0.86; sulpiride versus bromocriptine z=-1.29, p=0.39; sulpiride versus placebo z=-1.78, p=0.18; Tukey corrected for multiple comparisons). As evident from the plot, the analogous analysis within the forced trials revealed no difference in reaction RTs between drug treatments (placebo versus bromocriptine z=-0.46, p=0.89; sulpiride versus bromocriptine z=-0.85, p=0.67; sulpiride versus placebo z=-0.41, p=0.91; Tukey corrected for multiple comparisons).

fMRI results

As described above, two key analyses were performed. Our first analysis treated the entire duration of the bidding (equal to RT, mean RT±SD = 4.1±1.37s) as the period of interest to identify regions sensitive to value and dopaminergic modulation (Model 1, Figure 1B). Next we sought to determine whether in these regions, there were differential effects of dopamine on different aspects of the bidding process (Model 2, Figure 1C). Model 2 examined whether the drug effects were specific to a particular stage of each trial. Dividing every trial into early and late phases (corresponding approximately to initial valuation and value-dependent action) on the basis of the response made, we explored the interaction between drug, value (bid size) and trial phase (early versus late).

The neural representation of value (Model 1)

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

Examination of the brain regions involved in valuation across all study participants revealed activity correlating with subjective value within the pre-defined region of vmPFC (p_{FWE}<0.05, small volume corrected, Figure 3A), consistent with theory and previous work (Bartra et al., 2013; Clithero and Rangel, 2013). Further, several clusters were seen (whole-brain cluster-level p_{FWE}<0.05) including a large cluster encompassing the left and right posterior parietal cortex (maxima located in the region of intraparietal sulcus (IPS) on both sides) and extending to the left fusiform gyrus and further clusters in middle and inferior frontal gyri bilaterally and in the right fusiform/lingual gyrus (Figure 3B and Table 1). For completeness, we conducted two additional analyses. Firstly, we explored the correlation of neural activity with free and forced bids separately. Whereas the neural activity correlating with free bids in free trials mimicked the pattern of neural activity in our main contrast, there was no region, even at a liberal threshold of p<0.001 uncorrected, whose activity correlated with forced bids in forced trials. This confirms that the effects established in our main contrast were not driven by activity associated with forced trials. Secondly, we also investigated whether there was a region whose activity tracked the mismatch between free bid and the randomly ascribed forced bid for the same food item during forced trials. That is, we determined whether being forced to make a bid that markedly deviated from how one would normally value a given item was associated with enhanced responses. However, no such region was detected, even at a liberal threshold of p<0.001 uncorrected. Dopaminergic drugs modulate the neural response to value in the left and right inferior parietal gyrus/intraparietal sulcus (Model 1)

We next explored the effect of the administered dopaminergic drugs on the valuationdependent brain activity. The ANOVA comprising the three levels of pharmacological treatment found no effect of treatment in the vmPFC (this was also true for a more liberal threshold,

p<0.001 uncorrected). A significant effect of dopaminergic treatment was found in the right middle frontal gyrus and in the left and right inferior parietal gyrus, in close vicinity of the IPS (IPG/IPS; p<0.001 uncorrected, k>20 voxels; Table 2, Figure 4A).

To establish more precisely what drove this effect, additional two-sample t-tests were performed. Compared to sulpiride, bromocriptine was associated with a stronger relationship between value and activity in the IPG/IPS bilaterally (corrected for multiple comparisons at the cluster-level, p_{FWE} <0.05, Table 3, Figures 4B and 4D); in other words, it increased the strength of correlation between the bids and the BOLD response. Further t-tests between individual pharmacological treatments did not reveal any significant clusters at the same threshold.

Interestingly, these two clusters were close to the posterior parietal cluster identified in the previous contrast. As can be seen from the parameter estimates (Figure 4C), there was a trend towards reduced neural representation of value within the sulpiride group in the posterior parietal cluster, however, the clear distinction between the groups was only seen in the L- and R-IPG/IPS clusters.

In summary, we found that the neural response to value is significantly affected by pharmacological manipulation of dopaminergic function in the IPG/IPS region and this effect was driven by the bromocriptine versus sulpiride contrast.

Dopaminergic treatment modulates the neural representation of value in the left inferior parietal gyrus/intraparietal sulcus during the late stage of valuation (Model 2)

Here, we investigated whether the dopaminergic modulation is specific to the early or late stage of the valuation process. We focused specifically on the regions showing an effect of drug across the whole trial, splitting this trial into early and late phases (with the split-point determined based on time-to-decision for each trial separately). A significant time-by-drug interaction was established in a 10mm-radius sphere around the peak voxel in the left IPG/IPS demonstrating the strongest effect of dopaminergic treatment in the previous model (p_{FWE} <0.05, small volume

corrected, Table 4, Figure 5A). As evident from the parameter estimates extracted from each of six conditions (Figure 5B), the effect of dopaminergic manipulation on valuation was greater during the later (value-dependent action) phase compared to the earlier (initial valuation) phase. This result suggests that the modulation of strength of correlation between the bids and the BOLD signal in the left IPG/IPS, increasing with bromocriptine and decreasing with sulpiride, becomes more pronounced closer to the point when an appropriate action is used to record the final bid, i.e. when the participant makes a fine-grained decision about whether the bid should be 20p more or less, which in the context of our task might indicate a dopaminergic influence on the fine tuning of the valuation process.

Discussion

In this pharmacological fMRI study we used the established BDM mechanism with food rewards, in a sample of hungry participants, to assess the role of dopamine in subjective valuation. We characterised the effects of dopaminergic modulation, using both an agonist and an antagonist, demonstrating its role in the coding of value in the IPS. Compared to sulpiride, bromocriptine enhanced the neural representation of value in the IPS. Moreover, a significant drug-by-value-by-trial phase interaction indicated that the dopaminergic modulation of neural response was specific to the late phase of the trials, when an action was needed to record the value.

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

417

418

419

420

421

422

423

424

While there is a rich literature on the role of dopamine in value learning (Bayer and Glimcher, 2005; Schultz, 1998; Schultz et al., 1997; Steinberg et al., 2013; Wise, 2004), there is relatively little exploring its role in value computation during decision-making. Recent studies in healthy adults and patients with Parkinson's disease have partly addressed this using a probabilistic learning/choice task, demonstrating that dopamine biases choice towards more valuable options (Jocham et al., 2011; Shiner et al., 2012; Smittenaar et al., 2012) and enhances the expression of value in the vmPFC (Jocham et al., 2011). However, the learning nature of these tasks prevents a clear dissociation of dopaminergic effects on learning and performance/choice (particularly given that in Jocham et al. (2011) the dopamine-modulated prediction error expressed during the learning phase also predicted choice in the performance phase). Our results concur with these findings, and complement them by demonstrating a dopaminergic component of value computation in response to already well-learned items. Furthermore, the realistic nature of the task and the inclusion of highly-familiar foods as auction items more closely mimics every day value computations we make, which, compared to choosing between probabilistic stimulus-reward associations, are more complex and are thought to entail integration of various attributes into a single measure of subjective value, which can be then used as input for making choices (Rangel et al., 2008).

443

442

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

Interestingly, while our first analysis ("Model 1") replicated previous work in showing value signals in several brain regions including vmPFC (Bartra et al., 2013; Clithero and Rangel, 2013; Hunt et al., 2012; O'Doherty, 2011), only in the IPS was value representation modulated by dopamine. The finding of a dopaminergic effect in the IPS and not in the vmPFC, and the relatively late timing of this signal, suggests that a different, dopamine-sensitive value computation is being processed in the IPS. We are cautious about interpreting a null effect in vmPFC but it is worth noting that the association of BOLD activity in this region with value has been generally established at the initial stages of the decision-making process and is thought to serve as an input to later stages of decision-making (Rangel, 2010; Rangel and Clithero, 2013). Conversely, posterior parietal cortex has been implicated as central to action-based decisionmaking (Dorris and Glimcher, 2004; Musallam et al., 2004; Platt and Glimcher, 1999; Sugrue et al., 2004). Notably, one part of this region, the lateral intraparietal area has been found to represent a spatial map for guiding saccades (Snyder et al., 1997), and to encode the value of rewards associated with individual saccades (Dorris and Glimcher, 2004; Platt and Glimcher, 1999; Sugrue et al., 2004). The parietal reach region analogously represents the movement of forelimbs (Baumann et al., 2009; Connolly et al., 2003; Scherberger and Andersen, 2007), and the firing of these neurons correlates with the expected value of the movement's outcome (Musallam et al., 2004). These findings suggest that these two areas encode the value of movements. Human studies have also related measures of action value to activity in the IPS/posterior parietal cortex (Chowdhury et al., 2013; Gershman et al., 2009; Hunt et al., 2012; Iyer et al., 2010; Wunderlich et al., 2009).

One possibility is that dopaminergic enhancement of the neural representation of value reflects an increase in the signal to noise ratio (SNR) of the value representation. Evidence for this comes from studies of the decline in dopamine function with aging (reviewed in Bäckman et al., (2006)). Neural network simulations modelling age-related decline in dopaminergic function as attenuated gain control of SNR (Eppinger et al., 2011; Li et al., 2001) have suggested a plausible mechanistic link between reduced dopaminergic function, attenuated neural representation of

the value of stimuli and impairments in decision-making. Furthermore, studies in older adults demonstrated that the increased BOLD signal temporal variability (Samanez-Larkin et al., 2010a) and reduced neural representation of expected value (Samanez-Larkin et al., 2010b) were predictive of poorer decision-making. Our results complement these findings by directly showing the effects of dopaminergic modulation on the neural representation of value. Moreover, the fact that the drug modulations occurred late in the trials (i.e. close to the final selection of the bid) suggests that dopamine modulates the dynamic process of fine tuning the neural representation of value as the basis for completing the decision/action.

Behaviourally, we did not detect an effect of dopaminergic treatment on the magnitude of bids, perhaps as consequence of the relatively mild pharmacological perturbation induced. However, the presence of significant neural alterations in the context of matched behaviour offers some advantages to interpreting the former more clearly, in keeping with previous theoretical perspectives (Wilkinson and Halligan, 2004). Moreover, to the best of our knowledge, there is no data demonstrating that dopamine increases value in a context dissociated from learning, A more detailed analysis of the RTs revealed that the average time to decide on the size of the bid was reduced in the sulpiride condition, suggestive of decreased deliberation on the value of individual foods. Interestingly, this effect was paralleled by a trend towards larger bids in the sulpiride condition. In fact, the average bid under sulpiride is much closer to the mean bid in the forced condition (see Figure 2A). Given that the bids in the forced condition were taken from a random, uniform distribution, we speculate that sulpiride, and the proposed decrease in SNR of value representation, were associated with more random, less deliberative bids.

Finally, it is noteworthy that part of the posterior parietal region lying in close proximity to the dopamine-dependent value coding region identified in this study has been found to be related to goal-directed behaviour (Glascher et al., 2010). Given that dopamine has been implicated in mediating the balance between the habitual and goal-directed systems, with increased dopaminergic activity shifting the behaviour towards a more dominant goal-directed control

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

(de Wit et al., 2011, 2012; Wunderlich et al., 2012), and given the importance of valuation in goal-directed behaviour, we speculate that our agonist and antagonist drugs shifted this balance in different directions with the former promoting more measured, goal-directed responding and the latter, through reducing value SNR, prompting more rapid responses divorced from goal values. Of course, this is a speculation and our experimental design does not allow us to test it directly.

Certain limitations must be acknowledged. The between-subject design prevented analyses of potential brain-behaviour correlations. Further, while pharmacological fMRI is widely used and provides a targeted, non-invasive way of investigating neural processes, there are some basic limitations of the approach. Given the limited data on dose and receptor occupancy relationships for these agents, doses and administration protocols are based on the known pharmacokinetics of these drugs and on previous studies that have successfully used them to perturb dopaminergic function (Cools et al., 2009; Dodds et al., 2009; Mehta et al., 2008; Morcom et al., 2010). Dosages are also limited by what can be deemed clinically tolerable for healthy volunteers. Furthermore, there are studies reporting effects different from our findings - namely, enhanced neural value representation and improvement in performance associated with D2 antagonists, presumably linked to pre-synaptic auto-receptors effects (Jocham et al., 2011; Frank and O'Reilly, 2006). The preponderance of post-versus pre-synaptic effects is believed to vary depending on the exact drug used, its concentration, the basal level of dopamine in the system (discussed in Frank and O'Reilly (2006)), as well as on the brain area of the studied effect, given the different distribution of post- and pre-synaptic receptors throughout the brain (Kilts et al., 1987). It is not possible to entirely exclude the possibility of auto-receptors effects in our study though the directionally of our effects does instil some confidence that we are seeing predominantly post-synaptic effects.

In summary, we explored the role of dopamine in the neural representation of value without the confound of learning. We investigated the direct role of dopamine in the expression of value that

has been already learned through life experience, and whose accurate expression is a requisite of goal-directed behaviour. Our results suggest that dopamine enhances the neural representation of value in the IPS. The effect predominates towards the end of the valuation process, at the point where the decision becomes explicit in action. These findings provide a dopamine-dependent mechanism underlying impaired decision-making in healthy individuals and clinical populations with reduced dopamine levels.

531 **References**

- Bäckman, L., Nyberg, L., Lindenberger, U., Li, S.-C., and Farde, L. (2006). The correlative triad
- among aging, dopamine, and cognition: Current status and future prospects. Neurosci. Biobehav.
- 534 Rev. 30, 791–807.
- Bartra, O., McGuire, J.T., and Kable, J.W. (2013). The valuation system: A coordinate-based meta-
- analysis of BOLD fMRI experiments examining neural correlates of subjective value.
- 537 NeuroImage *76*, 412–427.
- Baumann, M.A., Fluet, M.-C., and Scherberger, H. (2009). Context-Specific Grasp Movement
- Representation in the Macaque Anterior Intraparietal Area. J. Neurosci. 29, 6436–6448.
- Bayer, H.M., and Glimcher, P.W. (2005). Midbrain dopamine neurons encode a quantitative
- reward prediction error signal. Neuron *47*, 129–141.
- Becker, G.M., DeGroot, M.H., and Marschak, J. (1964). Measuring utility by a single-response
- sequential method. Behav. Sci. 9, 226–232.
- Berridge, K.C., and Robinson, T.E. (1998). What is the role of dopamine in reward: hedonic
- impact, reward learning, or incentive salience? Brain Res. Rev. 28, 309–369.
- Caley, C.F., and Weber, S.S. (1995). Sulpiride: an antipsychotic with selective dopaminergic
- antagonist properties. Ann. Pharmacother. 29, 152–160.
- 548 Chib, V.S., Rangel, A., Shimojo, S., and O'Doherty, J.P. (2009). Evidence for a Common
- Representation of Decision Values for Dissimilar Goods in Human Ventromedial Prefrontal
- 550 Cortex. J. Neurosci. 29, 12315 –12320.
- 551 Chowdhury, R., Guitart-Masip, M., Lambert, C., Dayan, P., Huys, Q., Düzel, E., and Dolan, R.J.
- 552 (2013). Dopamine restores reward prediction errors in old age. Nat. Neurosci. 16, 648–653.
- 553 Clithero, J.A., and Rangel, A. (2013). Informatic parcellation of the network involved in the
- computation of subjective value. Soc. Cogn. Affect. Neurosci. nst106.
- 555 Connolly, J.D., Andersen, R.A., and Goodale, M.A. (2003). FMRI evidence for a "parietal reach
- region" in the human brain. Exp. Brain Res. 153, 140–145.
- Cools, R., Frank, M.J., Gibbs, S.E., Miyakawa, A., Jagust, W., and D'Esposito, M. (2009). Striatal
- 558 Dopamine Predicts Outcome-Specific Reversal Learning and Its Sensitivity to Dopaminergic
- 559 Drug Administration. J. Neurosci. *29*, 1538–1543.
- 560 Dodds, C.M., Clark, L., Dove, A., Regenthal, R., Baumann, F., Bullmore, E., Robbins, T.W., and
- Müller, U. (2009). The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD
- signal during the manipulation of information in working memory. Psychopharmacology (Berl.)
- 563 *207*, 35–45.
- Dorris, M.C., and Glimcher, P.W. (2004). Activity in Posterior Parietal Cortex Is Correlated with
- the Relative Subjective Desirability of Action. Neuron *44*, 365–378.
- Eppinger, B., Hämmerer, D., and Li, S.-C. (2011). Neuromodulation of reward-based learning and
- decision making in human aging. Ann. N. Y. Acad. Sci. 1235, 1–17.
- Fiorillo, C.D., Tobler, P.N., and Schultz, W. (2003). Discrete coding of reward probability and
- uncertainty by dopamine neurons. Science *299*, 1898–1902.

- 570 Frank, M.J., and O'Reilly, R.C. (2006). A mechanistic account of striatal dopamine function in
- 571 human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav.
- 572 Neurosci. 120, 497–517.
- 573 Frank, M.J., Seeberger, L.C., and O'reilly, R.C. (2004). By carrot or by stick: cognitive
- 574 reinforcement learning in parkinsonism. Science *306*, 1940–1943.
- 575 Gershman, S.J., Pesaran, B., and Daw, N.D. (2009). Human Reinforcement Learning Subdivides
- 576 Structured Action Spaces by Learning Effector-Specific Values. J. Neurosci. *29*, 13524–13531.
- Glascher, J., Daw, N., Dayan, P., and O'Doherty, J.P. (2010). States versus Rewards: Dissociable
- 578 neural prediction error signals underlying model-based and model-free reinforcement learning.
- 579 Neuron *66*, 585–595.
- Grether, D.M., Plott, C.R., Rowe, D.B., Sereno, M., and Allman, J.M. (2007). Mental processes and
- strategic equilibration: An fMRI study of selling strategies in second price auctions. Exp. Econ.
- 582 *10*, 105–122.
- Hothorn, T., Bretz, F., and Westfall, P. (2008). Simultaneous inference in general parametric
- 584 models. Biom. J. Biom. Z. 50, 346–363.
- Hunt, L.T., Kolling, N., Soltani, A., Woolrich, M.W., Rushworth, M.F.S., and Behrens, T.E.J. (2012).
- Mechanisms underlying cortical activity during value-guided choice. Nat. Neurosci. 15, 470–476,
- 587 S1-3.
- Iyer, A., Lindner, A., Kagan, I., and Andersen, R.A. (2010). Motor Preparatory Activity in Posterior
- Parietal Cortex is Modulated by Subjective Absolute Value. PLoS Biol. 8.
- Jocham, G., Klein, T.A., and Ullsperger, M. (2011). Dopamine-Mediated Reinforcement Learning
- 591 Signals in the Striatum and Ventromedial Prefrontal Cortex Underlie Value-Based Choices. J.
- 592 Neurosci. *31*, 1606–1613.
- Kilts, C.D., Anderson, C.M., Ely, T.D., and Nishita, J.K. (1987). Absence of synthesis-modulating
- 594 nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal
- populations. J. Neurosci. Off. J. Soc. Neurosci. 7, 3961–3975.
- 596 Kvernmo, T., Härtter, S., and Burger, E. (2006). A review of the receptor-binding and
- 597 pharmacokinetic properties of dopamine agonists. Clin. Ther. 28, 1065–1078.
- Li, S.C., Lindenberger, U., and Sikström, S. (2001). Aging cognition: from neuromodulation to
- representation. Trends Cogn. Sci. 5, 479–486.
- 600 McClure, S.M., Daw, N.D., and Montague, P.R. (2003). A computational substrate for incentive
- salience. Trends Neurosci. 26, 423-428.
- 602 Mehta, M.A., Montgomery, A.J., Kitamura, Y., and Grasby, P.M. (2008). Dopamine D2 receptor
- occupancy levels of acute sulpiride challenges that produce working memory and learning
- impairments in healthy volunteers. Psychopharmacology (Berl.) 196, 157–165.
- 605 Morcom, A.M., Bullmore, E.T., Huppert, F.A., Lennox, B., Praseedom, A., Linnington, H., and
- Fletcher, P.C. (2010). Memory encoding and dopamine in the aging brain: a
- 607 psychopharmacological neuroimaging study. Cereb. Cortex N. Y. N 1991 20, 743–757.
- Musallam, S., Corneil, B.D., Greger, B., Scherberger, H., and Andersen, R.A. (2004). Cognitive
- 609 Control Signals for Neural Prosthetics. Science *305*, 258–262.

- Niv, Y., Daw, N.D., Joel, D., and Dayan, P. (2007). Tonic dopamine: opportunity costs and the
- 611 control of response vigor. Psychopharmacology (Berl.) 191, 507–520.
- 612 O'Doherty, J.P. (2011). Contributions of the ventromedial prefrontal cortex to goal-directed
- 613 action selection. Ann. N. Y. Acad. Sci. *1239*, 118–129.
- Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., and Frith, C.D. (2006). Dopamine-dependent
- prediction errors underpin reward-seeking behaviour in humans. Nature 442, 1042–1045.
- Pinheiro, J., Bates, D., and Sarkar, D. (2013). nlme: Linear and Nonlinear Mixed Effects
- 617 Modelsnlme: Linear and Nonlinear Mixed Effects Models.
- Plassmann, H., O'Doherty, J., and Rangel, A. (2007). Orbitofrontal Cortex Encodes Willingness to
- Pay in Everyday Economic Transactions. J. Neurosci. 27, 9984–9988.
- Platt, M.L., and Glimcher, P.W. (1999). Neural correlates of decision variables in parietal cortex.
- 621 Nature 400, 233-238.
- Rangel, A., Camerer, C., and Montague, P.R. (2008). A framework for studying the neurobiology
- of value-based decision making. Nat. Rev. Neurosci. 9, 545–556.
- Robbins, T.W., and Everitt, B.J. (2007). A role for mesencephalic dopamine in activation:
- 625 commentary on Berridge (2006). Psychopharmacology (Berl.) 191, 433–437.
- Roesch, M.R., Calu, D.J., and Schoenbaum, G. (2007). Dopamine neurons encode the better option
- in rats deciding between differently delayed or sized rewards. Nat. Neurosci. 10, 1615–1624.
- 628 Samanez-Larkin, G.R., Kuhnen, C.M., Yoo, D.J., and Knutson, B. (2010a). Variability in nucleus
- accumbens activity mediates age-related suboptimal financial risk taking. J. Neurosci. Off. J. Soc.
- 630 Neurosci. *30*, 1426.
- 631 Samanez-Larkin, G.R., Wagner, A.D., and Knutson, B. (2010b). Expected value information
- improves financial risk taking across the adult life span. Soc. Cogn. Affect. Neurosci. nsq043.
- 633 Scherberger, H., and Andersen, R.A. (2007). Target selection signals for arm reaching in the
- posterior parietal cortex. J. Neurosci. Off. J. Soc. Neurosci. 27, 2001–2012.
- 635 Schultz, W. (1998). Predictive reward signal of dopamine neurons. J. Neurophysiol. *80*, 1–27.
- 636 Schultz, W., Dayan, P., and Montague, P.R. (1997). A Neural Substrate of Prediction and Reward.
- 637 Science *275*, 1593–1599.
- 638 Shiner, T., Seymour, B., Wunderlich, K., Hill, C., Bhatia, K.P., Dayan, P., and Dolan, R.J. (2012).
- Dopamine and performance in a reinforcement learning task: evidence from Parkinson's
- 640 disease. Brain 135, 1871–1883.
- 641 Smittenaar, P., Chase, H.W., Aarts, E., Nusselein, B., Bloem, B.R., and Cools, R. (2012).
- Decomposing effects of dopaminergic medication in Parkinson's disease on probabilistic action
- selection learning or performance? Eur. J. Neurosci. 35, 1144–1151.
- 644 Snyder, L.H., Batista, A.P., and Andersen, R.A. (1997). Coding of intention in the posterior
- 645 parietal cortex. Nature *386*, 167–170.
- 646 Steinberg, E.E., Keiflin, R., Boivin, J.R., Witten, I.B., Deisseroth, K., and Janak, P.H. (2013). A causal
- link between prediction errors, dopamine neurons and learning. Nat. Neurosci. 16, 966–973.

648 Sugrue, L.P., Corrado, G.S., and Newsome, W.T. (2004). Matching Behavior and the Representation of Value in the Parietal Cortex. Science 304, 1782–1787. 649 650 Tobler, P.N., Fiorillo, C.D., and Schultz, W. (2005). Adaptive Coding of Reward Value by Dopamine Neurons. Science 307, 1642-1645. 651 Wiesel, F.A., Alfredsson, G., Ehrnebo, M., and Sedvall, G. (1980). The pharmacokinetics of 652 intravenous and oral sulpiride in healthy human subjects. Eur. J. Clin. Pharmacol. 17, 385–391. 653 654 Wilkinson, D., and Halligan, P. (2004). The relevance of behavioural measures for functionalimaging studies of cognition. Nat. Rev. Neurosci. 5, 67–73. 655 Wise, R.A. (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5, 483–494. 656 De Wit, S., Barker, R.A., Dickinson, A.D., and Cools, R. (2011). Habitual versus goal-directed 657 658 action control in Parkinson disease. J. Cogn. Neurosci. 23, 1218–1229. 659 De Wit, S., Standing, H.R., Devito, E.E., Robinson, O.J., Ridderinkhof, K.R., Robbins, T.W., and Sahakian, B.J. (2012). Reliance on habits at the expense of goal-directed control following 660 dopamine precursor depletion. Psychopharmacology (Berl.) 219, 621–631. 661 Wunderlich, K., Rangel, A., and O'Doherty, J.P. (2009). Neural computations underlying action-662 based decision making in the human brain. Proc. Natl. Acad. Sci. U. S. A. 106, 17199–17204. 663 Wunderlich, K., Smittenaar, P., and Dolan, R.J. (2012). Dopamine enhances model-based over 664 model-free choice behavior. Neuron 75, 418-424. 665 (2012a). Bromocriptine SPC. 666 (2012b). Domperidone SPC. 667 668 669

670

Figure legends

Figure 1. Task structure and model specification. 671 A. The auction task featured 50 snack items presented as part of free and forced trials. Free and 672 673 forced trials, of duration 8s, were presented in a randomised order. After the bidding trial was over, a 1s feedback screen showing the final bid was presented. This was followed by a 0.5s 674 blank screen. On 30 random occasions during the course of the task, a 6s null trial with a 675 fixation cross was presented after the blank screen. 676 B. fMRI model 1 schematic. Each bidding trial was modelled as a boxcar function (depicted as a 677 pink rectangle), from the onset of the food stimulus until the bid was confirmed (duration equal 678 to RT). 679 C. fMRI model 2 schematic. Two time points within each bidding trial were modelled as events 680 within the trial (0s stick or delta functions, depicted as pink rectangles): an early phase 681 regressor set at the time of food stimulus onset, and a late phase regressor set at a time half-way 682 from the food photo onset to the bid confirmation (RT/2), separately for each trial. 683 Figure 2. Behavioural results. 684 A. Average bid by treatment group in the free trial condition. Error bars represent SEM of each 685 subject's average bid. Presented on the same graph is the mean of the uniform distribution of 686 instructed forced bids. 687 B. Average RT by treatment group and trial type. Error bars represent SEM of each subject's 688 average RT. 689 690 691

Dopamine	modulates	the	neural	representatio	n of	subjective	value	of food	in	hungry
subjects										

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

Figure 3. Neural representation of value. Significant areas of activation were rendered onto a standard SPM8 T1 template image, with corronal and sagittal sections presented at the coordinates appropriate for displaying relevant regions. A. The neural representation of value was found within the pre-defined 10mm-radius sphere in the vmPFC region (p_{FWE}<0.05, small-volume corrected). B. Equally, value-coding clusters were found in regions surviving the whole-brain correction at the cluster-level (p_{FWE}<0.05). These include a large cluster encompassing the left and right posterior parietal cortex (maxima located in the region of IPS on both sides) and extending to the left fusiform gyrus and further clusters in middle and inferior frontal gyri bilaterally and in the right fusiform / lingual gyrus. Full details of the activation foci are given in Table 1. Figure 4. Dopaminergic modulation of the neural representation of value. Significant areas of activation were rendered onto the standard SPM8 T1 template image, with corronal and sagittal sections presented at the coordinates appropriate for displaying relevant regions. A. Activation areas in the left and right IPG/IPS and in the right middle frontal gyrus that exhibited an effect of drug on the neural representation of value (p<0.001 uncorrected, k>20 voxels). B. Displayed in green are the activation areas in the left and right IPG/IPS in which there was an enhancement of the neural representation of value in the bromocriptine compared to the sulpiride treatment group (p_{FWE}<0.05, whole-brain corrected at the cluster-level). Value-coding

subjects 714 clusters, common to all three treatment groups, are presented in magenta ((p_{FWE}<0.05, wholebrain corrected at the cluster-level). 715 716 C. Presented inside the magenta box are the parameter estimates of the neural representation of 717 value averaged per treatment groups, extracted from the large value-coding cluster spanning the left and right posterior parietal cortex (presented in magenta on the images in panel B). 718 D. Presented inside the green box are the parameter estimates of the neural representation of 719 value averaged per treatment groups, extracted from the left and right IPG/IPS clusters of the 720 bromocriptine versus sulpiride contrast (presented in green on the images in panel B). 721 Error bars represent SEM. Full details of the activation foci are given in Tables 2 and 3. 722 Figure 5. Dopaminergic treatment modulates the neural representation of value in the 723 left inferior parietal gyrus/intraparietal sulcus during the late stage of valuation. 724 Corronal (at y=-54mm to the anterior commissure) and sagittal sections (at x=-54mm to the left 725 726 of the mid-line) from the standard SPM8 T1 template image. A. The analysis was confined to a 10mm-radius sphere around the voxel in the left IPG/IPS that 727 728 showed the strongest dopamine-dependent modulation in model 1, and is depicted here in green. Presented in yellow are the voxels within this sphere showing a significant treatment 729 730 (placebo, bromocriptine, sulpiride) by time (early, late) interaction. For display purposes, both 731 contrasts are presented at p<0.01 uncorrected. B. Presented inside the yellow box are the parameter estimates of the neural representation of 732 value for each of the six conditions: treatment (placebo/bromocriptine/sulpiride) and time 733 (early/late). The parameter estimates were extracted from the voxels exhibiting the treatment-734 by-time interaction within the described sphere (presented in yellow on the image in panel A). 735 Error bars represent SEM. Full details of the activation foci are given in Table 4. 736

- 737 <u>Table legends</u>
- 738 **Table 1.** Regions correlated with subjective value.
- **Table 2.** Regions exhibiting a dopaminergic modulation of the neural representation of value.
- **Table 3.** Regions with an enhanced neural representation of value under bromocriptine,
- 741 compared to sulpiride.
- **Table 4.** Activation peak exhibiting a time-by-treatment interaction in the left IPG/IPS.

Figures

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



Tables

Table 1 Regions correlated with subjective value.

	Side	Cluster	Peak MN coordinates			Peak scores	
		Size					
Region			x	у	Z	т	z
Intraparietal Sulcus	L/R	7354	-26	-66	46	6.4	5.32
Middle Frontal Gyrus	L	425	-24	2	58	5.75	4.91
Middle Frontal Gyrus	R	744	25	-1	54	5.5	4.74
Fusiform Gyrus/Lingual Gyrus	R	833	28	-64	-8	5.24	4.57
Inferior Frontal Gyrus	R	604	50	6	26	4.86	4.3
Middle Frontal Gyrus	R	286	46	42	10	4.25	3.86
Inferior Frontal Gyrus	L	248	-48	2	34	4.1	3.74
Anterior Cingulate/Medial Frontal Gyrus*	L/R	81	0	44	2	3.71	3.43

p<0.05 whole-brain FWE correction for multiple comparisons at the cluster-level (p<0.001 uncorrected threshold).

^{*}Survives p<0.05 small-volume FWE correction within a 10mm sphere around the vmPFC coordinates (-3, 42, -6) from the work of Chib et al. (2009).

Table 2 Regions exhibiting a dopaminergic modulation of the neural representation of value.

	Side	Cluster Size	Peak MNI coordinates			Peak scores	
Region			x	Y	Z	F	Z
Middle Frontal Gyrus	R	55	32	0	58	12.62	3.86
Inferior Parietal Gyrus/Intraparietal Sulcus	L	63	-50	-50	46	11.17	3.63
Inferior Parietal Gyrus/Intraparietal Sulcus	R	40	52	-50	48	9.95	3.42

p<0.001 uncorrected, extent k>20 voxels.

 $Table\ 3\ Regions\ with\ an\ enhanced\ neural\ representation\ of\ value\ under\ bromocriptine,\ compared\ to\ sulpiride.$

	Side	Cluster Size	Peak MNI coordinates			Peak scores		
Region			x	у	z	Т	Z	
Inferior Parietal Gyrus/Intraparietal Sulcus	L	494	-50	-50	46	4.66	4.14	
Inferior Parietal Gyrus/Intraparietal Sulcus	R	363	52	-50	48	4.45	3.99	

p<0.05 whole-brain FWE correction for multiple comparisons at the cluster-level (p<0.001 uncorrected threshold).

Table 4 Activation peak exhibiting a time-by-treatment interaction in the left IPG/IPS.

Si		Cluster Size	Peak M	NI coordinat	Peak sc	Peak scores	
Region			x	Υ	Z	F	Z
Inferior Parietal	L	10	-54	-54	50	8.79	3.39

Gyrus/Intraparietal Sulcus

p<0.05 small-volume FWE correction within a 10mm sphere around the peak voxel in the left IPG/IPS (-50,-50, 46) which showed an effect of drug across the entire bidding trial (model 1).